コミュニティにおけるアルツハイマー病の病理学的流行
Dag Aarsland1,2, Anita Lenora Sunde3,4, Diego A Tovar-Rios5,6,7,8
1Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway. daarsland@gmail.com.
Nature
|December 17, 2025
まとめ
アルツハイマー病
科学分野:
- 神経学
- バイオマーカー
- 高齢者医療
背景:
- アルツハイマー病の神経病理学的変化 (ADNCs) は認知障害の主な原因ですが,その流行率はよく確立されていません.
- 血液ベースのバイオマーカーは,ADNCを評価するためのスケーラブルな方法を提供します.
- トレオニン217 (p-tau217) で酸化されたタウはADNCの重要な指標である.
研究 の 目的:
- 血のp-tau217を用いて,ノルウェーの集団におけるADNCの流行を推定する.
- 高齢者のアルツハイマー病の臨床前,プロドロマ,および認知症の進行率を決定する.
- ADNCと認知状態 (認知症,軽度の認知障害,認知機能不全) の関連性を評価する.
主な方法:
- ノルウェーの集団ベースのコホート (57歳以上の個人) の11,486個のプラズマサンプルを分析した.
- プラズマp-tau217をADNCの代替マーカーとして測定
- 認知状態のADNCの年齢層別流行の推定と分析.
主要な成果:
- ADNCの罹患率は年齢とともに増加し,< 8% (58~69. 9歳) から65. 2% (> 90歳) に達した.
- 70歳以上の個体では,臨床前のAD: 10%,プロドロマのAD: 10. 4%,ADの認知症: 9. 8%
- 70歳以上の患者のうち,ADNCは認知症の60%で,MCIの32. 6%で,認知障害のない23. 5%で発見されました.
結論:
- 研究結果によると アルツハイマー病の認知症は 以前考えられていたより 高齢者に多く見られます
- 臨床前アルツハイマー病の流行は,以前に推定されたより若いグループで低い可能性があります.
- 血p-tau217は,集団研究における大規模なADNCの評価のための貴重なツールです.
さらに関連する動画
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.5K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
関連する概念動画
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
